Abstract 3099: Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysis
Ophélia Maertens(American Institutes for Research), Samuel B. Ho, Neil T. Umbreit(Harvard University), Vivek Rauniyar(University of California, Berkeley), Fallon Lin(Novartis (United States)), Ying Huang(Boston Biomedical (United States)), Anna Uvarova(American Institutes for Research), Eric Fang(Adamas Pharmaceuticals (United States)), Imad Hanna(Novartis (Switzerland)), Bradley French(American Institutes for Research), Sajan P. Joseph(Boston Biomedical (United States))
Cited by 0
Related Papers
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
|Nature|2016|925
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
|Cell|2015|377
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
|Cancer Discovery|2012|297
Enantioselective Halocyclization Using Reagents Tailored for Chiral Anion Phase-Transfer Catalysis
|Journal of the American Chemical Society|2012|265